First human trial launches for experimental cancer drug targeting HER2 tumors
Disease control
ENROLLING_BY_INVITATION
This early-stage study is testing a new experimental drug called ZV0203 in patients with advanced HER2-positive solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand how the drug moves through the body. Researc…
Phase: PHASE1 • Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC